MRKMerck Sharp & Dohme LLCSigning up patients
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Von Hippel-Lindau Disease · Malignant Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Mar 23, 2026
- Main results expected
- Apr 22, 2034
- Fully finished
- Apr 22, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort A and Cohort B: Overall Survival (OS)
Measured over: Up to approximately 7 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07405164 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC